ORIGINAL INVESTIGATION
|
|
- Melvyn Williamson
- 5 years ago
- Views:
Transcription
1 ORIGINAL INVESTIGATION Diagnostic and Therapeutic Implications of Relationships Between Fasting, 2-Hour Postchallenge Plasma Glucose and Hemoglobin A 1c Values Hans J. Woerle, MD; Walkyria P. Pimenta, MD; Christian Meyer, MD; Niyaz R. Gosmanov, MD; Ervin Szoke, MD; Tamas Szombathy, MD; Asimina Mitrakou, MD; John E. Gerich, MD Background: Increased fasting plasma glucose (FPG) and 2-hour postchallenge plasma glucose (PCPG) levels with normal hemoglobin A 1c (HbA 1c ) levels are recognized as risk factors for cardiovascular disease. We undertook this study to determine the relationships between FPG and 2-hour PCPG levels over the normal HbA 1c range and to assess the need to control FPG and 2-hour PCPG levels to achieve HbA 1c targets recommended by the American Diabetes Association (ADA), International Diabetes Federation (IDF), and American College of Endocrinology (ACE). Methods: The data of all healthy individuals with HbA 1c values less than 7.0% (N=457) who underwent oral glucose tolerance tests between 1986 and 2002 for either screening as potential research volunteers (93%) or diagnostic purposes (7%) were analyzed. Results: Of 404 individuals with normal HbA 1c levels ( 6.0%), 60% had normal glucose tolerance, 33% had impaired glucose tolerance, 1% had isolated impaired FPG, and 6% had type 2 diabetes mellitus. Of 161 individuals without normal glucose tolerance, 80% had normal FPG levels. Both FPG and 2-hour PCPG levels increased as HbA 1c increased and were significantly correlated (r=0.63, P.001), but the 2-hour PCPG level increased at a rate 4 times greater than FPG and accounted for a greater proportion of HbA 1c. People who met the IDF and ACE HbA 1c targets ( 6.5%) had significantly lower 2-hour PCPG levels than those who met the ADA target ( 7.0%) (P=.03), whereas FPG levels were similar. Conclusions: Most individuals with HbA 1c values between 6.0% and 7.0% have normal FPG levels but abnormal 2-hour PCPG levels, suggesting that an upper limit of normal for FPG at 110 mg/dl (6.11 mmol/l) is too high and that attempts to lower HbA 1c in these individuals will require treatment preferentially directed at lowering postprandial glucose levels. Arch Intern Med. 2004;164: Author affiliations are listed at the end of this article. The authors have no relevant financial interest in this article. N-TERMINAL VALINE RESIdues of erythrocyte hemoglobin become irreversibly glycosylated in proportion to circulating glucose concentrations, and the resultant product is commonly referred to as hemoglobin A 1c (HbA 1c ). 1 Because of the halflife of the erythrocyte, the percentage of hemoglobin represented by HbA 1c provides an index of the average plasma glucose concentration during the previous 2 to 3 months. 1 Consequently, HbA 1c measurements have become the preferred method to monitor long-term glycemic control in patients with diabetes mellitus 2 and have been used in clinical trials to assess the efficacy of antidiabetic medications and the impact of therapeutic interventions on diabetic complications. 3-5 Data from both epidemiological studies 6,7 and controlled clinical trials 3-5 indicate that lower HbA 1c levels are associated with reduced risks for both microvascular and macrovascular diabetic complications. The American Diabetes Association (ADA) currently recommends an HbA 1c treatment target of 7.0% or less primarily to reduce microvascular complications. 8 The International Diabetes Federation (IDF) 9 and the American College of Endocrinology (ACE), 10 taking into consideration cardiovascular disease (CVD), both recommend a treatment target of 6.5% or less. The Council for the Advancement of Diabetes Research and Education recommends the lowest HbA 1c achievable without unacceptable side effects. 11 Although HbA 1c levels accurately reflect long-term glycemia, several issues remain. One is the relative contributions of fasting plasma glucose (FPG) and postchallenge plasma glucose (PCPG) concentrations. 12 Such knowledge would be important when choosing among therapeutic options to achieve the different recommended glycemic targets, especially when HbA 1c values are near the upper limit of normal Another important issue concerns the use of HbA 1c, FPG, and 2-hour PCPG val- 1627
2 Table 1. Characteristics of 404 Individuals With Normal HbA 1c Values ( 6.0%)* FPG, mg/dl 2-Hour PCPG, mg/dl HbA 1c, % Age, y BMI Sex, M/F Normal glucose tolerance (n = 243) 85.7 ± ± ± ± ± /162 Impaired glucose tolerance (n = 132) 97.0 ± ± ± ± ± /79 Isolated impaired fasting glucose tolerance (n = 5) ± ± ± ± ± 1.7 2/3 Type 2 diabetes mellitus (n = 24) ± ± ± ± ± /8 Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by the square of height in meters); FPG, fasting plasma glucose; SI conversion factor: To convert glucose to millimoles per liter, multiply by *Data are mean ± SD unless otherwise indicated. ues for diagnostic purposes. In 1997, the ADA 17 and the World Health Organization (WHO) 18 revised their criteria for normal glucose tolerance (NGT): the upper limit of normal for FPG was reduced from 126 to 109 mg/dl ( mmol/l). The FPG values between 110 and 126 mg/dl (6.11 and 6.99 mmol/l) were designated as impaired fasting glucose (IFG) by the ADA. Two-hour values during the standard oral glucose tolerance test (2- hour PCPG) diagnostic of impaired glucose tolerance (IGT) (values between 140 and 200 mg/dl [7.77 and mmol/ L]) and diabetes (values 200 mg/dl [11.10 mmol/l]) remained the same. The ADA (but not the IDF and WHO) currently recommends that the FPG be used diagnostically in preference to the oral glucose tolerance test. 17 An implicit assumption of this recommendation was that IFG would have the same significance as IGT regarding the risk for development of type 2 diabetes mellitus and its complications. However, several studies 19,20 have challenged this assumption. Furthermore, the ADA recommendation has been questioned, because numerous studies 12-14,21-24 have demonstrated that an appreciable number of individuals with a normal FPG level will have an abnormal 2-hour PCPG level and thus their condition will go undiagnosed and untreated. The clinical significance of this is underscored by the fact that hyperglycemia has been identified as an independent and continuous risk factor for CVD, 6 the major cause of mortality in people with type 2 diabetes mellitus. 25,26 Thus, in addition to patients with type 2 diabetes mellitus 25 or IGT, 13,19,27 it now appears that individuals with FPG and HbA 1c values in the upper normal range are also at increased risk for CVD. 20,28,29 This increased risk of CVD for individuals with HbA 1c levels in the normal range has been recently reinforced by the Norfolk cohort of the European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk) study. 30 This was a 2- to 4-year follow-up of 4662 men aged 45 to 79 years that found that individuals with HbA 1c levels between 5.0% and 5.4% had a 2.5-fold increased risk of dying of CVD compared with individuals with HbA 1c levels below 5.0%. Moreover, individuals with HbA 1c values between 5.5% and 6.9% had a 2-fold increase in overall mortality. Unfortunately, that study provided no data regarding FPG and 2-hour PCPG levels, and hence it was not possible to assess their relative impact. We undertook the present study to determine the relative contribution of FPG and 2-hour PCPG levels to HbA 1c over the normal HbA 1c range, as well as those values analyzed in the EPIC-Norfolk study, and to assess the need to control FPG and 2-hour PCPG levels to achieve HbA 1c targets recommended by the ADA, IDF, and ACE. METHODS STUDY DESIGN From 1986 through 2002, data were systematically collected from all individuals undergoing standard oral glucose tolerance tests performed as recommended by the ADA 31 in whom simultaneous HbA 1c levels were determined (N=607). 1 Of these individuals, 457 hadhba 1c levelsbelow7.0%,andtheirdatawereselectedforstudy. Most individuals (93%) were responders to advertisements for healthy volunteers for research studies, and the remainder (7%) were referred for evaluation of glucose tolerance status. Three individuals had been previously diagnosed as having diabetes but their condition was being managed by diet alone. None of the individuals were taking medications known to affect glucose tolerance. All were in apparent good health based on medical history, physical examination results, and routine laboratory tests. The patients were largely non-hispanic white (59%); 13% were of Hispanic origin, 22% were of mixed Hispanic European, African American, and Native American background, and 6% were African American. Plasma glucose values were determined by a glucoseanalyzer(ysiinc,yellowsprings,ohio,orbeckmancoulter Inc, Fullerton, Calif); the coefficient of variation for glucose values of 50 to 250 mg/dl ( mmol/l) was approximately 1%.HemoglobinA 1c valuesweredeterminedbyhigh-performance liquidchromatography(bio-radlaboratories, Hercules, Calif; reference range, 4.0%-6.0%; coefficient of variation, 3.6%). STATISTICAL ANALYSES Data are given as mean±sd unless otherwise specified and were analyzed using Statistica statistical software (1998 edition, Statsoft Inc, Tulsa, Okla). Normality of the distribution of HbA 1c values was assessed using the Kolmogorov-Smirnov test. Comparisons between groups were performed using analysis of variance followed by the Scheffé test. The contributions of changes in FPG and 2-hour PCPG levels to changes in HbA 1c levels were assessed using multiple linear regression. P.05 was considered statistically significant. RESULTS Using ADA, IDF, and WHO criteria, 20,32, individuals had NGT (Table 1). Their HbA 1c level was 5.05%±0.47%, resulting in an upper limit of normal (mean±2 SD) of 5.99%. The HbA 1c values were normally distributed and comparable to those found in large population-based studies such as the Third National Health and 1628
3 Table 2. Deciles of 457 Individuals With HbA 1c Values up to 7.0%* Decile FPG, mg/dl 2-Hour PCPG, mg/dl HbA 1c, % Age, y BMI Sex, M/F ± ± ± ± ± / ± ± ± ± ± 4.0 9/ ± ± ± ± ± / ± ± ± ± ± / ± ± ± ± ± 4.4 9/ ± ± ± ± ± / ± ± ± ± ± / ± ± ± ± ± / ± ± ± ± ± / ± ± ± ± ± /25 Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by the square of height in meters); FPG, fasting plasma glucose; SI conversion factor: To convert glucose to millimoles per liter, multiply by *Data are mean ± SD unless otherwise indicated. Nutrition Examination Survey (NHANES III) (mean±sd, 5.3%±0.4%; N=2284) 34 and the Telecom Study (5.05%±0.5%, N=3240). 35 Thus, although not a population-based survey, our results appear to be representative of the general population. The mean±sd FPG and 2-hour PCPG values were 85.7±8.3 mg/dl (4.76±0.46 mmol/l) and 103.1±18.6 mg/dl (5.72±1.03 mmol/l), respectively, yielding upper limits of normal of 102 and 140 mg/dl (5.66 and 7.77 mmol/l), respectively. An additional 161 individuals had an HbA 1c level below the upper limit of normal (Table 1), but abnormal glucose tolerance. Of those with a normal HbA 1c level (n=404), 86% with IGT had a normal FPG level, as did 63% with type 2 diabetes mellitus. In contrast, only 5 individuals (1%) had an abnormal FPG level with a normal 2-hour PCPG level (isolated IFG). To assess the contribution of FPG and 2-hour PCPG levels to HbA 1c levels in the EPIC-Norfolk study and to evaluate the need for control of FPG and 2-hour PCPG levels for HbA 1c targets of the ADA, WHO, and IDF, we also included for analysis all subjects with HbA 1c levels between 6.0% and 7.0% (n=53). None had NGT, 23 (43%) had IGT, 26 (49%) had type 2 diabetes mellitus, and 4 (8%) had isolated IFG. Of all those with abnormal glucose tolerance having an HbA 1c level less than 7.0% (n=205), 152 (74%) had normal FPG levels (82% of those with IGT and 48% of those with type 2 diabetes mellitus), confirming the insensitivity of FPG for detecting abnormal glucose tolerance ,21-24 The data of all subjects (N=457) were divided into deciles according to their HbA 1c level (Table 2). Figure 1 shows the distribution of these individuals according to categories of glucose tolerance. The frequency of abnormal glucose tolerance (IGT, isolated IFG, and type 2 diabetes mellitus) increased with HbA 1c from less than 10% in the first decile (4.33%±0.27%) to % in the tenth decile (6.46%±0.23%). The FPG and 2-hour PCPG levels were significantly correlated (r=0.63, P.001) (Figure 2), and although both increased as HbA 1c level increased, 2-hour PCPG concentrations increased by a much greater extent (Figure 3). For every 1% increase in HbA 1c level, 2-hour PCPG level increased nearly 4 times as much as that for FPG (47 vs 12 mg/dl [2.61 vs 0.67 mmol/l]). Subjects in Deciles, % Type 2 Diabetes Mellitus IGT Isolated IFGT 4.33 ± ± ± ± ± ± ± ± ± ± 0.23 Deciles of HbA 1c Values, % Figure 1. Proportion of individuals (N=457) with impaired glucose tolerance (IGT), type 2 diabetes mellitus, and isolated impaired fasting glucose tolerance (IFGT) according to hemoglobin A 1c (HbA 1c ) deciles. To determine the relative contribution of FPG and 2-hour PCPG to HbA 1c, multiple linear regression analysis was performed in which HbA 1c was the dependent variable and FPG, 2-hour PCPG, body mass index, sex, and age (Table 3) were independent variables. The overall correlation coefficient was (P.001). Only FPG (P.001), 2-hour PCPG (P.001), and age (P=.02) contributed significantly. The partial regression coefficient for the 2-hour PCPG (.346) was nearly 1.5 times greater than that for the FPG (.238), indicating that increases in the 2-hour PCPG level explained approximately 50% more of the increase in HbA 1c than did the FPG. Table 4 gives the characteristics of subjects subdivided by HbA 1c as in the EPIC-Norfolk study. Of 107 individuals with HbA 1c levels below 5.0%, 16% had abnormal glucose tolerance (15% had either IGT or isolated IFG, and 1% had type 2 diabetes mellitus). Of the 181 individuals with HbA 1c levels of 5.0% to 5.4%, 37% had abnormal glucose tolerance (32% had either IGT or isolated IFG, and 5% had type 2 diabetes mellitus). Of 169 individuals with HbA 1c values of 5.5% to 6.9%, 77% had abnormal glucose tolerance (53% had either IGT or isolated IFG, and 24% had type 2 diabetes mellitus). Currently, both the IDF 9 and ACE 10 recommend a target HbA 1c of 6.5% or lower, whereas the ADA recom- 1629
4 2-Hour Postchallenge Plasma Glucose, mg/dl Table 3. Multiple Linear Regression of Factors Contributing to HbA 1c * Factor (SEM) P Value FPG.238 (.050) Hour PCPG.346 (.053).001 Age.105 (.045).02 BMI.049 (.039).20 Sex.025 (.040).51 Abbreviations: BMI, body mass index; FPG, fasting plasma glucose; *Overall equation: HbA 1c = 0.238(FPG) (2-hour PCPG) (age) ; r= Fasting Plasma Glucose, mg/dl Table 4. Characteristics of Individuals by EPIC-Norfolk HbA 1c Categories Figure 2. Correlation between fasting plasma glucose and 2-hour postchallenge plasma glucose levels in individuals (N=457) with hemoglobin A 1c values of less than 7% (y=2.13x 60.3, r=0.63, P.001). To convert glucose to millimoles per liter, multiply by Fasting Plasma Glucose, mg/dl 2-Hour Postchallenge Plasma Glucose, mg/dl HbA 1c, % 6 7 Figure 3. Changes in fasting plasma glucose (y=11.9x+30, r=0.48, P.001) and 2-hour postchallenge plasma glucose (y=46.8x 105, r=0.55, P.001) as a function of hemoglobin A 1c (HbA 1c ) levels (N=457). To convert glucose to millimoles per liter, multiply by mends a target of 7.0% or lower. 8 Table 5 compares FPG and 2-hour PCPG values of individuals with HbA 1c levels of 6.0% to 6.5% and 6.6% to 7.0%; FPG values of these groups were not significantly different from one another and were only slightly above the current upper limit of normal (110.9 mg/dl [6.16 mmol/l]). However, people Characteristics No. of patients Sex, M/F 30/77 74/107 60/109 Age, mean ± SD, y 37.1 ± ± 13.1* 50.1 ± 13.8* BMI, mean ± SD 26.4 ± ± ± 4.7* FPG, mean ± SD, mg/dl 85.8 ± ± 12.4*.2 ± 15.9* 2-Hour PCPG, ± ± 38.6* ± 51.9* mean ± SD, mg/dl HbA 1c, mean ± SD, % 4.60 ± ± 0.14* 5.91 ± 0.39* Normal glucose tolerance, % Impaired glucose tolerance, % Isolated impaired fasting glucose tolerance, % Type 2 diabetes mellitus, % with HbA 1c levels of 6.6% to 7.0% had 2-hour PCPG levels significantly greater than those with HbA 1c levels between 6.0% and 6.5% (225.8±50.5 mg/dl vs 198.3±55.8 mg/dl [12.53±2.80 mmol/l vs 11.01±3.10 mmol/l], P=.03). Moreover, their 2-hour PCPG levels were on average 2-fold greater than those of individuals with NGT (103.1 mg/dl [5.72 mmol/l], Table 1). COMMENT HbA 1c Group, % Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by the square of height in meters); EPIC-Norfolk, Norfolk cohort of the European Prospective Investigation of Cancer and Nutrition; FPG, fasting plasma glucose; SI conversion factor: To convert glucose to millimoles per liter, multiply by *P.01 vs the less than 5.0% HbA 1c group. The key findings of this study are that with the reference range for HbA 1c, (1) FPG and 2-hour PCPG levels are significantly correlated and both increase as HbA 1c increases, but (2) 2-hour PCPG levels increase at a much greater rate thanfpglevelsandcontributemoretotheincreaseinhba 1c levels; (3) 2-hour PCPG levels are a more sensitive indicator of abnormal glucose tolerance than either FPG or HbA 1c ; and (4) the main difference in individuals satisfying HbA 1c goals recommended by the IDF and ACE ( 6.5%) com- 1630
5 Table 5. Characteristics of Individuals Grouped by HbA 1c Values HbA 1c Group, % Characteristics No. of patients Sex, M/F 14/23 8/8 Age, mean ± SD, y 54.6 ± ± 12.6 BMI, mean ± SD 27.8 ± ± 3.7 FPG, mean ± SD mg/dl ± ± 21.5* 2-Hour PCPG, mean ± SD, mg/dl ± ± 50.5 HbA 1c, mean ± SD, % 6.26 ± ± 0.09 Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by the square of height in meters); FPG, fasting plasma glucose; SI conversion factor: To convert glucose to millimoles per liter, multiply by *P =.89. P =.03. pared with that recommended by the ADA ( 7.0%) relates to postprandial hyperglycemia. The correlation we found between FPG and 2-hour PCPG, although highly significant (P.001), was modest (r=0.63), explaining approximately 40% of the variation. This could reflect the importance of unmeasured variables (eg, physical fitness), variability in the FPG and 2-hour PCPG levels, 36 and imprecision in the measurements of plasma glucose. Similarly, multiple linear regression indicated that FPG, 2-hour PCPG, and age explained only approximately 35% of the variation in HbA 1c. In addition to the previously mentioned factors, one must consider that only a single value was used to reflect postprandial hyperglycemia and more of the variation might have been explained had more sampling times been used, such as with continuous plasma glucose monitoring. 36 Nevertheless, it would have to be assumed that the measurements on a single day accurately reflected the average of the preceding 2 to 4 months, which is what the HbA 1c is thought to reflect. To our knowledge, ours is the only study to examine the relationships between fasting and postprandial plasma glucose levels and HbA 1c values in people with HbA 1c values within the reference range. However, Monnier et al 36 recently examined the relative contribution of fasting and postprandial plasma glucose levels to day long hyperglycemia in people with type 2 diabetes whose HbA 1c values ranged from below 6% to above 9%. These investigators sampled plasma glucose levels at 8 AM,11 AM, 2PM, and 5 PM and divided their 290 subjects into quintiles based on HbA 1c levels; they found that as HbA 1c increased, the contribution of postprandial plasma glucose levels to day long hyperglycemia decreased from approximately 70% (lowest quintile) to approximately 30% in the highest quintile. The patients studied by Monnier et al 36 in their lowest quintile had an HbA 1c level virtually identical to that of our subjects in our highest decile (ie, 6.45% vs 6.46%). Thus, our conclusion that postprandial hyperglycemia contributes approximately 1.5 times more to HbA 1c than do FPG levels in individuals with normal or near-normal HbA 1c values is consistent with the findings of Monnier et al 36 in their lowest-hba 1c -quintile subjects (eg, a 70% contribution of postprandial hyperglycemia would represent 2.3-fold the contribution of fasting hyperglycemia). Indeed, in our subjects with HbA 1c values between 6% and 7% (Table 5), FPG levels were increased above normal by approximately 3 mg/dl (0.17 mmol/l), whereas their 2-hour PCPG levels were increased by approximately 70 mg/dl (3.89 mmol/l). Our findings that most people with IGT have a normal FPG level and that in these individuals and those with NGT the 2-hour PCPG level contributes more to HbA 1c than the FPG have several important clinical implications. These observations suggest that the increased risk for CVD found in people with IGT and normal HbA 1c levels could be attributable to postprandial hyperglycemia. This conclusion is further supported by our evaluation of FPG and 2-hour PCPG levels of individuals with HbA 1c values similar to those of the EPIC-Norfolk study. That study found that HbA 1c values between 5.0% and 5.4% were associated with a 2.5-fold increased risk of death from CVD and ischemic heart disease. 30 We found that 81% of individuals with HbA 1c values between 5.0% and 5.5% had a normal FPG level, whereas only 58% had a normal 2-hour PCPG level. Impaired glucose tolerance is widely recognized as a precursor of type 2 diabetes mellitus and a risk factor for CVD. 5,17,18 Pharmacologic and lifestyle interventions have been shown to improve IGT and reduce the risk of developing type 2 diabetes mellitus. The IDF recommends that if IGT cannot be reversed by lifestyle changes, pharmacologic intervention should be considered. 20 Thus, identification of individuals with IGT is important. However, numerous studies 12-14,20-24 indicate that use of only FPG determinations, as currently recommended by the ADA, is suboptimal. Our data confirm these findings in that of all individuals in our database with IGT (n=155), only 17% had an abnormal FPG level, 14,20,21,24 which supports the WHO and IDF 18,20 recommendations that the oral glucose tolerance be the main diagnostic procedure. A recent IDF consensus panel suggested that one reason for the lack of sensitivity of the FPG in detecting IGT is that the upper current limit of normal for FPG may be too high. 20 Our data support this view. Individuals in our database with NGT had a mean FPG level of 85.7 mg/dl (4.76 mmol/l) (Table 1), a value identical to that found in a meta-analysis of 34 published studies, including NHANES III data (ie, 85.7 mg/dl [4.76 mmol/l]). 41 Since the standard deviation of FPG in our study was 8.3 mg/dl (0.46 mmol/l), this implies an upper limit of normal (mean±2 SD) of 102 mg/dl (5.66 mmol/l), which is less than the currently accepted value of 109 mg/dl (6.05 mmol/l). The ADA currently recommends an HbA 1c value of less than 7.0% as a target for acceptable glycemic control primarily based on the risk for microvascular complications. 8 However, macrovascular complications account for most of the morbidity and mortality in people with type 2 diabetes mellitus. 25,26 On the basis of epidemiological data that suggest that a lower HbA 1c level may be needed to prevent these complications, 6,20 the IDF and ACE recommend an HbA 1c target of 6.5% or less. 9,10 Our data indicate that the difference in achieving IDF and ACE targets vs that recommended by the ADA would largely depend on reducing postprandial hyperglycemia, since 1631
6 individuals who met the IDF, ACE, and ADA targets had similar FPG levels and differed only in 2-hour PCPG levels. This conclusion is supported by the recent study of Monnier et al, 36 which showed that in type 2 diabetic patients with HbA 1c values that averaged less than 7.3%, postprandial hyperglycemia accounted for approximately 70% of day long hyperglycemia. Since this manuscript was accepted for publication, the ADA has reduced its upper limit of normal for FPG to mg/dl. Accepted for publication September 16, From the Department of Medicine, University of Rochester School of Medicine, Rochester, NY (Drs Woerle, Meyer, Gosmanov, Szoke, Szombathy, and Gerich); Department of Clinical Medicine, Faculdade de Medicina Botucatu, University of São Paulo State, São Paulo, Brazil (Dr Pimenta); and Diabetes-Metabolism Unit, Henry Dunant Hospital, Athens, Greece (Dr Mitrakou). Dr Woerle is now with the Department of Internal Medicine II, Ludwig-Maximilians- University of Munich, Munich, Germany; Dr Meyer, with the Department of Endocrinology and Metabolism, Carl T. Hayden Veterans Affairs Medical Center, Phoenix, Ariz; and Dr Szombathy, with the Department of Medicine, Unity Health System, Rochester. This study was supported in part by grant 5MO1 RR from the Division of Research Resources, General Clinical Research Center, Bethesda, Md, and grant DK from the National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda. We thank Mary Little for her excellent editorial assistance and the nursing and laboratory staff of the General Clinical Research Center for their superb help. Correspondence: John E. Gerich, MD, Department of Medicine, University of Rochester School of Medicine, 601 Elmwood Ave, Campus Box MED/CRC, Rochester, NY (johngerich@compuserve.com). REFERENCES 1. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2002;48: American Diabetes Association. Tests of glycemia in diabetes. Diabetes Care. 2002; 25(suppl 1):S97-S UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354:602]. Lancet. 1998;352: Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med. 1993;329: Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28: Coutinho M, Gerstein H, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. Diabetes Care. 1999;22: Stratton I, Adler A, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321: American Diabetes Association. Standards of care for patients with diabetes mellitus. Diabetes Care. 2002;25(suppl 1):S33-S Standl E. International Diabetes Federation European Policy Group standards for diabetes. Endocr Pract. 2002;8(suppl 1): Corbin R, Davidson J, Ganda O, et al. American College of Endocrinology consensus statement on guidelines for glycemic control. Endocr Pract. 2002;8 (suppl 1): CADRE s A1c position [editorial]. Curr Diabetes Pract. 2002;1: American Diabetes Association. Postprandial blood glucose. Diabetes Care. 2001; 24: DECODE Study Group; European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161: Caputo S, Pitocco D, Ruotolo V, Ghirlanda G. What is the real contribution of fasting plasma glucose and postprandial glucose in predicting HbA1c and overall blood glucose control [letter]? Diabetes Care. 2001;24: Saydah S, Loria C, Eberhardt M, Brancati F. Subclinical states of glucose intolerance and risk of death in the US. Diabetes Care. 2001;24: Goldberg R, Mellies M, Sacks F, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Circulation. 1998;98: Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20: Alberti K, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15: Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care. 1999;22: Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia. Diabet Med. 2002;19: Barzilay J, Spiekerman C, Wahl P, et al. Cardiovascular disease in older adults with glucose disorders. Lancet. 1999;354: de Vegt F, Dekker J, Ruhé H, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia. 1999;42: Gerstein H. Fasting versus postload glucose levels: why the controversy? Diabetes Care. 2001;24: Shaw J, Zimmet P, de Courten M, et al. Impaired fasting glucose or impaired glucose tolerance: what best predicts future diabetes in Mauritius? Diabetes Care. 1999;22: Laakso M, Lehto S. Epidemiology of macrovascular disease in diabetes. Diab Rev. 1997;5: Stamler J, Vaccaro O, Neaton J, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16: Shaw J, Hodge A, de Courten M, Chitson P, Zimmet P. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia. 1999;42: Gerstein H. Is glucose a continuous risk factor for cardiovascular mortality? Diabetes Care. 1999;22: Balkau B, Bertrais S, Ducimetiere P, Eschwege E. Is there a glycemic threshold for mortality risk? Diabetes Care. 1999;22: Khaw K-T, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ. 2001;322: National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28: Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1998;21(suppl 1):S5-S World Health Organization Expert Committee. Diabetes Mellitus: A Second Report. Geneva, Switzerland: World Health Organization Expert Committee; 1980: Technical Report Series Davidson M, Schriger D, Peters A, Lorber B. Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. JAMA. 1999;281: Simon D, Senan C, Garnier P, Saint-Paul M, Papoz L. Epidemiological features of glycated haemoglobin A1c distribution in a healthy population: the Telecom Study. Diabetologia. 1989;32: Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26: Tuomilehto J, Lindström J, Eriksson J, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344: Knowler W, Barrett-Connor E, Fowler S, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346: Pan X-R, Li G-W, Hu Y-H, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. Diabetes Care. 1997;20: Chiasson J, Josse R, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus. Lancet. 2002;359: Peters AL, Davidson MB, Schriger DL, Hasselblad V; Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. JAMA. 1996;276:
Post-challenge hyperglycaemia is associated with premature death and macrovascular complications
Diabetologia (2003) 46[Suppl1]:M17 M21 DOI 10.1007/s00125-002-0932-4 Post-challenge hyperglycaemia is associated with premature death and macrovascular complications Q. Qiao 1, 2, J. Tuomilehto 2, 3, K.
More informationIsolated Post-challenge Hyperglycemia: Concept and Clinical Significance
CLINICAL PRACTICE Isolated Post-challenge Hyperglycemia: Concept and Clinical Significance John MF. Adam*, Daniel Josten** ABSTRACT The American Diabetes Association has strongly recommended that fasting
More informationKeywords Cardiovascular diseases. Diabetes. Diabetic nephropathy. Dysglycaemia. Renal. Risk
Diabetologia (005) 48: 749 755 DOI 0.007/s005-005-858-4 ARTICLE H. C. Gerstein. J. Pogue. J. F. E. Mann. E. Lonn. G. R. Dagenais. M. McQueen. S. Yusuf. HOPE investigators The relationship between dysglycaemia
More informationNormal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis
CLINICAL RESEARCH STUDY Normal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis Gregory A. Nichols, PhD, Teresa A. Hillier, MD, MS, Jonathan B. Brown, PhD, MPP Center for Health Research, Kaiser
More informationImplementation Conference for ACE Outpatient Diabetes Mellitus Consensus Conference Recommendations: Position Statement.
Implementation Conference for ACE Outpatient Diabetes Mellitus Consensus Conference Recommendations: Position Statement February 2, 2005 Over 20 million Americans suffer from diabetes; approximately one
More informationMoving to an A1C-Based Screening & Diagnosis of Diabetes. By Prof.M.Assy Diabetes&Endocrinology unit
Moving to an A1C-Based Screening & Diagnosis of Diabetes By Prof.M.Assy Diabetes&Endocrinology unit is the nonenzymatic glycated product of the hemoglobin beta-chain at the valine terminal residue. Clin
More informationFasting Glucose, Obesity, and Metabolic Syndrome as Predictors of Type 2 Diabetes: The Cooper Center Longitudinal Study
Fasting Glucose, Obesity, and Metabolic Syndrome as Predictors of Type 2 Diabetes: The Cooper Center Longitudinal Study Laura F. DeFina, MD,* Gloria Lena Vega, PhD,Þ David Leonard, PhD,Þ and Scott M. Grundy,
More informationPasta: A High-Quality Carbohydrate Food
Pasta: A High-Quality Carbohydrate Food Cyril W.C. Kendall Department of Nutritional Sciences, Faculty of Medicine, University of Toronto; Clinical Nutrition & Risk Factor Modification Center, St. Michael
More informationHyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin
Diabetologia (2004) 47:385 394 DOI 10.1007/s00125-004-1334-6 Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin T. Nakagami the DECODA Study
More informationDiabetes mellitus is diagnosed and characterized by chronic hyperglycemia. The effects of
Focused Issue of This Month Early Diagnosis of Diabetes Mellitus Hyun Shik Son, MD Department of Internal Medicine, The Catholic University of Korea College of Medicine E - mail : sonhys@gmail.com J Korean
More informationDiabetes: Staying Two Steps Ahead. The prevalence of diabetes is increasing. What causes Type 2 diabetes?
Focus on CME at the University of University Manitoba of Manitoba : Staying Two Steps Ahead By Shagufta Khan, MD; and Liam J. Murphy, MD The prevalence of diabetes is increasing worldwide and will double
More informationThe threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group
Diabetologia (2006) 49: 822 827 DOI 10.1007/s00125-006-0189-4 ARTICLE N. G. Forouhi. B. Balkau. K. Borch-Johnsen. J. Dekker. C. Glumer. Q. Qiao. A. Spijkerman. R. Stolk. A. Tabac. N. J. Wareham. On behalf
More informationORIGINAL INVESTIGATION. Hemoglobin A 1c Level and Future Cardiovascular Events Among Women
ORIGINAL INVESTIGATION Hemoglobin A 1c Level and Future Cardiovascular Events Among Women Gavin J. Blake, MD, MPH, MSc, MRCPI; Aruna D. Pradhan, MD, MPH; JoAnn E. Manson, MD, DrPH; G. Rhys Williams, ScD;
More informationInitiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationThe Efficacy and Cost of Alternative Strategies for Systematic Screening for Type 2 Diabetes in the U.S. Population Years of Age
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E The Efficacy and Cost of Alternative Strategies for Systematic Screening for Type 2 Diabetes in the U.S. Population 45 74
More informationThe Effect of Lowering the Threshold for Diagnosis of Impaired Fasting Glucose
Yonsei Med J 49(2):217-223, 2008 DOI 10.3349/ymj.2008.49.2.217 The Effect of Lowering the Threshold for Diagnosis of Impaired Fasting Glucose So Hun Kim, 1 Wan Sub Shim, 1 Eun A Kim, 1 Eun Joo Kim, 1 Seung
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.043
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationGlycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk)
Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk) Kay-Tee Khaw, Nicholas Wareham, Robert Luben, Sheila
More informationWILL YOU USE HBA1C TO SCREEN & MONITOR DIABETES? Dr. Amany Mousa
WILL YOU USE HBA1C TO SCREEN & MONITOR DIABETES? Dr. Amany Mousa Diabetes is clinically well defined by glycation of proteins 1. True 2. false So far, diabetes has been defined as a clinical condition
More informationIn 1997, an International Expert
Follow-up Report on the Diagnosis of Diabetes Mellitus Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Reprinted with permission from Diabetes Care 26:3160 3167, 2003 In 1997,
More informationIt is estimated that diabetes will affect 380 million people
Fasting Glucose and Retinopathy as a Diabetes Diagnosis Results from three diverse population-based studies found no uniform fasting plasma glucose glycemic threshold for retinopathy. BY GERALD LIEW, MD;
More informationORIGINAL INVESTIGATION. Short-term Variability in Measures of Glycemia and Implications for the Classification of Diabetes
ORIGINAL INVESTIGATION Short-term Variability in Measures of Glycemia and Implications for the Classification of Diabetes Elizabeth Selvin, PhD, MPH; Ciprian M. Crainiceanu, PhD; Frederick L. Brancati,
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationPlasma Glucose and Prediction of Microvascular Disease and Mortality
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Plasma Glucose and Prediction of Microvascular Disease and Mortality Evaluation of 1997 American Diabetes Association and
More informationHemoglobin A1c Predicts Diabetes but Not Cardiovascular Disease in Nondiabetic Women
The American Journal of Medicine (2007) 120, 720-727 CLINICAL RESEARCH STUDY Hemoglobin A1c Predicts Diabetes but Not Cardiovascular Disease in Nondiabetic Women Aruna D. Pradhan, MD, a,b,e Nader Rifai,
More informationReducing cardiovascular risk factors in patients with prediabetes
REVIEW Reducing cardiovascular risk factors in patients with prediabetes Jean-Louis Chiasson 1 & Sophie Bernard 1 Practice Points The prevalence of prediabetes is high and on the rise. Subjects with impaired
More informationEarly diagnosis, early treatment and the new diagnostic criteria of diabetes mellitus
British Journal of Nutrition (2000), 84, Suppl. 2, S177±S181 S177 Early diagnosis, early treatment and the new diagnostic criteria of diabetes mellitus Takeshi Kuzuya* JA Shioya General Hospital, Tomita
More informationJapan Foundation for the Promotion of International Medical Research Cooperation, Tokyo, Japan 2
Original Article 857 Fasting Plasma Glucose and Incidence of Diabetes --- Implication for the Threshold for Impaired Fasting Glucose: Results from the Population-Based Omiya MA Cohort Study Masayuki Kato,
More informationMetabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
More informationEpidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk. Eberhard Standl
Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk Eberhard Standl European Heart House Sophia Antipolis Thursday, June 17, 2010 IDF Diabetes Atlas 2009: Global Numbers Still
More informationBlood glucose variations and cardiovascular risk in patients with diabetes
Blood glucose variations and cardiovascular risk in patients with diabetes Thessaloniki 13 November 2009 Oliver Schnell, Executive Member of the Managing Board Diabetes Research Institute, Munich UKPDS
More informationImpaired Glucose Tolerance, Impaired Fasting Glycaemia and Cardiovascular Risk
R E V I E W A R T I C L E Impaired Glucose Tolerance, Impaired Fasting Glycaemia and Cardiovascular Risk Harsinen Sanusi ABSTRACT Type 2 Diabetes Mellitus tends to increase year by year and it has high
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationStrategies for the prevention of type 2 diabetes and cardiovascular disease
European Heart Journal Supplements (2005) 7 (Supplement D), D18 D22 doi:10.1093/eurheartj/sui025 Strategies for the prevention of type 2 diabetes and cardiovascular disease Jaakko Tuomilehto 1,2,3 *, Jaana
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationAddressing Addressing Challenges in Type 2 Challenges in Type 2 Diabetes Diabetes Speaker:
Addressing Challenges in Type 2 Diabetes Geneva Briggs, PharmD,, BCPS Addressing Challenges in Type 2 Diabetes Speaker: Dr. Geneva Clark Briggs, a board-certified Pharmacotherapy Specialist, received her
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More informationT he prevalence of type 2 diabetes
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Two-Step Approach for the Prediction of Future Type 2 Diabetes Risk MUHAMMAD A. ABDUL-GHANI, MD, PHD 1 TAMAM ABDUL-GHANI, MSC 1 MICHAEL P.
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationFrom Policemen to Policies: What Is the Future for 2-h Glucose?
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E From Policemen to Policies: What Is the Future for 2-h Glucose? The Kelly West Lecture, 2000 EVELINE ESCHWÈGE, MD 1 MARIE
More informationUsefulness of Glycated Hemoglobin as Diagnostic Criteria for Metabolic Syndrome
ORIGINAL ARTICLE Endocrinology, Nutrition & Metabolism http://dx.doi.org/10.3346/jkms.2012.27.9.1057 J Korean Med Sci 2012; 27: 1057-1061 Usefulness of Glycated Hemoglobin as Diagnostic Criteria for Metabolic
More informationPrimary Prevention of T2DM. KW Chan Endocrine & Diabetes Team Department of M&G, PMH 22 March 2009
Primary Prevention of T2DM KW Chan Endocrine & Diabetes Team Department of M&G, PMH 22 March 2009 Primary Prevention of T2DM Why to intervene? When to intervene? Lifestyle intervention Pharmacological
More informationPrevalence, Diagnosis, and Treatment of Impaired Fasting Glucose and Impaired Glucose Tolerance in Nondiabetic U.S. Adults
Epidemiology/Health Services Research O R I G I N A L A R T I C L E Prevalence, Diagnosis, and Treatment of Impaired Fasting Glucose and Impaired Glucose Tolerance in Nondiabetic U.S. Adults AMRITA KARVE,
More informationPre-Diabetes and the Risk for Cardiovascular Disease
Journal of the American College of Cardiology Vol. 55, No. 13, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.10.060
More informationPostprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence
Diabetologia 2001) 44: 2107±2114 Ó Springer-Verlag 2001 Reviews Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence E. Bonora, M. Muggeo
More information1472 Diabetes Care Volume 39, August 2016
1472 Diabetes Care Volume 39, August 2016 Prediabetes : Are There Problems With This Label? No, We Need Heightened Awareness of This Condition! Diabetes Care 2016;39:1472 1477 DOI: 10.2337/dc16-1143 William
More informationIMPORTANCE OF PRANDIAL GLUCOSE REGULATION IN THE MANAGEMENT OF CARDIOVASCULAR COMPLICATIONS IN TYPE 2 DIABETES MELLITUS
2013 ILEX PUBLISHING HOUSE, Bucharest, Roumania http://www.jrdiabet.ro Rom J Diabetes Nutr Metab Dis. 20(1):077-084 doi: 10.2478/rjdnmd-2013-0010 IMPORTANCE OF PRANDIAL GLUCOSE REGULATION IN THE MANAGEMENT
More informationAn analysis of baseline data from the ORIGIN trial
Epidemiology/Health Services Research O R I G I N A L A R T I C L E Relationship Between A1C and Fasting Plasma Glucose in Dysglycemia or Type 2 Diabetes An analysis of baseline data from the ORIGIN trial
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationCE on SUNDAY Newark, NJ October 18, 2009
CE on SUNDAY Newark, NJ October 18, 2009 Date: Sunday, October 18, 2009 Time: 2:45 PM 3:45 PM Location: Sheraton Newark Airport Hotel Title: Speaker(s): Addressing Challenges in Type 2 Diabetes ACPE #
More informationThe number of diabetic patients in Japan
Metabolic Syndrome/Insulin Resistance Syndrome/Pre-Diabetes O R I G I N A L A R T I C L E Glucose Intolerance Is Common in Japanese Patients With Acute Coronary Syndrome Who Were Not Previously Diagnosed
More informationNOTICE. Release of final Health Canada document: Standards for Clinical Trials in Type 2 Diabetes in Canada
September 24, 2007 NOTICE Our file number: 07-122151-509 Release of final Health Canada document: Standards for Clinical Trials in Type 2 Diabetes in Canada The final version of the Health Canada guidance
More informationWORLDWIDE, THE PREVAlence
ORIGINAL CONTRIBUTION Relation of Impaired Fasting and Postload Glucose With Incident Type 2 Diabetes in a Dutch Population The Hoorn Study Femmie de Vegt, PhD Jacqueline M. Dekker, PhD Agnes Jager, MD,
More informationDiabetes Care 29: , 2006
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Use of HbA 1c in Predicting Progression to Diabetes in French Men and Women Data from an Epidemiological Study on the Insulin Resistance
More informationHbA1c: A Marker for Severity of Acute Myocardial Infarction
International Journal of Interdisciplinary and Multidisciplinary Studies (IJIMS), 2016, Vol 3, No.4,48-52. 48 Available online at http://www.ijims.com ISSN: 2348 0343 HbA1c: A Marker for Severity of Acute
More informationThis article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and
This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution
More informationHperglycemia has been associated
Epidemiology/Health Services Research O R I G I N A L A R T I C L E GHb Level and Subsequent Mortality Among Adults in the U.S. SHARON SAYDAH, PHD 1 MIN TAO, PHD 2 1 GIUSEPPINA IMPERATORE, MD EDWARD GREGG,
More informationDiabetes Care Publish Ahead of Print, published online February 25, 2011
Pathophysiology/Complications O R I G I N A L A R T I C L E Diabetes Care Publish Ahead of Print, published online February 25, 2011 The Relationship Between b-cell Function and Glycated Hemoglobin Results
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationDiabetes Care 34: , 2011
Epidemiology/Health Services Research O R I G I N A L A R T I C L E Hemoglobin A 1c as a Diagnostic Tool for Diabetes Screening and New-Onset Diabetes Prediction A 6-year community-based prospective study
More informationReduced 10-year Risk of CHD in Patients who Participated in Communitybased DPP: The DEPLOY Pilot Study
Diabetes Care Publish Ahead of Print, published online December 23, 2008 Reduced 10-year CHD Risk: DEPLOY Pilot Study Reduced 10-year Risk of CHD in Patients who Participated in Communitybased DPP: The
More informationFasting and Postchallenge Glycemia and Cardiovascular Disease Risk
Pathophysiology/Complications O R I G I N A L A R T I C L E Fasting and Postchallenge Glycemia and Cardiovascular Disease Risk The Framingham Offspring Study JAMES B. MEIGS, MD, MPH 1 DAVID M. NATHAN,
More informationEndocr. J./ R. YAMAMOTO-HONDA et al.: BLOOD GLUCOSE AND HbA1c LEVELS IN DIABETIC PATIENTS doi: /endocrj.K08E-071
ORIGINAL Distribution of Blood Glucose and the Correlation between Blood Glucose and Hemoglobin A1c Levels in Diabetic Outpatients Ritsuko YAMAMOTO-HONDA 1, Hiroji KITAZATO 1, Shinji HASHIMOTO 2, Yoshihiko
More informationEffect of Aging on Glucose Homeostasis. Accelerated deterioration of -cell function in individuals with impaired glucose tolerance
Pathophysiology/Complications B R I E F R E P O R T Effect of Aging on Glucose Homeostasis Accelerated deterioration of -cell function in individuals with impaired glucose tolerance ERVIN SZOKE, MD 1 MUHAMMAD
More informationThe American Diabetes Association estimates
DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular
More informationOn May 2001, the Third Adult
THE RISK OF DIABETES: CAN WE IMPACT CHD THROUGH THE ATP III CHOLESTEROL GUIDELINES? * Based on a presentation given by Steven M. Haffner, MD, MPH ABSTRACT Diabetes has been recognized among diabetologists
More informationHemoglobin A1c Is Positively Correlated with Framingham Risk Score in Older, Apparently Healthy Nondiabetic Korean Adults
Original Article Endocrinol Metab 2013;28:103-109 http://dx.doi.org/10.3803/enm.2013.28.2.103 pissn 2093-596X eissn 2093-5978 Hemoglobin A1c Is Positively Correlated with Framingham Risk Score in Older,
More informationWhy Do We Care About Prediabetes?
Why Do We Care About Prediabetes? Complications of Diabetes Diabetic Retinopathy Leading cause of blindness in adults 1,2 Diabetic Nephropathy Leading cause of Kidney failure Stroke 2- to 4-fold increase
More informationANUMBER OF EPIDEMIOLOGIcal
ORIGINAL INVESTIGATION The Independent Effect of Type Diabetes Mellitus on Ischemic Heart Disease, Stroke, and Death A Population-Based Study of Men and Women With Years of Follow-up Thomas Almdal, DMSc;
More informationThe role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type 2 diabetes mellitus
Diabetologia (2003) 46[Suppl1]:M30 M36 DOI 10.1007/s00125-002-0934-2 The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type 2 diabetes mellitus E. Standl
More informationSanofi Announces Results of ORIGIN, the World s Longest and Largest Randomised Clinical Trial in Insulin in Pre- and Early Diabetes
PRESS RELEASE Sanofi Announces Results of ORIGIN, the World s Longest and Largest Randomised Clinical Trial in Insulin in Pre- and Early Diabetes Dublin, Ireland (15 June 2012) Sanofi presented results
More informationHemoglobin A1C and diabetes diagnosis: The Rancho Bernardo Study
Diabetes Care Publish Ahead of Print, published online October 16, 2009 Hemoglobin A1c and diabetes Hemoglobin A1C and diabetes diagnosis: The Rancho Bernardo Study Running Title: Hemoglobin A1c and diabetes
More informationBody: Re Should the threshold for definition of impaired fasting glucose be lowered?
From: dme_editorial@wiley.com To: inouek@m.u-tokyo.ac.jp CC: dme_editorial@wiley.com Subject: Diabetic Medicine DME-2009-00292 Body: Re Should the threshold for definition of impaired fasting glucose be
More informationUse of Glycated Hemoglobin in the Diagnosis of Diabetes Mellitus and Pre diabetes and Role of Fasting Plasma Glucose, Oral Glucose Tolerance Test
www.ijpm.in www.ijpm.ir Use of Glycated Hemoglobin in the Diagnosis of Diabetes Mellitus and Pre diabetes and Role of Fasting Plasma Glucose, Oral Glucose Tolerance Test Naser Alqahtani, Waseem Abdul Ghafor
More informationORIGINAL INVESTIGATION. Evaluation of the Framingham Risk Score in the European Prospective Investigation of Cancer Norfolk Cohort
ORIGINAL INVESTIGATION Evaluation of the Framingham Risk Score in the European Prospective Investigation of Cancer Norfolk Cohort Does Adding Glycated Hemoglobin Improve the Prediction of Coronary Heart
More informationType 2 diabetes is occurring in epidemic proportions
The Natural History of Progression From Normal Glucose Tolerance to Type 2 Diabetes in the Baltimore Longitudinal Study of Aging James B. Meigs, 1 Denis C. Muller, 2 David M. Nathan, 3 Deirdre R. Blake,
More informationmicrovascular complications (P=.0099) and a 16% risk reduction for myocardial infarction (P=.05) compared to conventional therapy. 8 Analysis of these
CONCISE REVIEW ASSESSING FOR GLYCEMIC CLINICIANS CONTROL Assessing Glycemic Control With Self-monitoring of Blood Glucose and Hemoglobin A 1c Measurements GEORGE DAILEY, MD Hemoglobin A 1c ( ) is the gold
More informationGlycemic control a matter of life and death
Glycemic control a matter of life and death Linda Garcia Mellbin MD PhD Specialist in Cardiology & Internal medicine Dep of Cardiology Karolinska University Hospital /Karolinska Institutet Mortality (%)
More informationDiabetes Care Publish Ahead of Print, published online February 23, 2011
Epidemiology/Health Services Research O R I G I N A L A R T I C L E Diabetes Care Publish Ahead of Print, published online February 23, 2011 Incidence of Type 2 Diabetes Using Proposed HbA 1c Diagnostic
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationImpaired Glucose Tolerance
Page 1 of 6 Impaired Glucose Tolerance If you have impaired glucose tolerance, your blood glucose is raised beyond the normal range but it is not so high that you have diabetes. However, if you have impaired
More informationAmerican Academy of Insurance Medicine
American Academy of Insurance Medicine October 2012 Dr. Alison Moy Liberty Mutual Dr. John Kirkpatrick Thrivent Financial for Lutherans 1 59 year old male, diagnosed with T2DM six months ago Nonsmoker
More informationAlthough type 2 diabetes is
F e a t u r e a r t i c l e Tests for Screening and Diagnosis of Type 2 Diabetes Mary E. Cox, MD, and David Edelman, MD Although type 2 diabetes is common and tests to screen for and diagnose it are widely
More informationGlycemic Variability:
Glycemic Variability: Do the Differences Make a Difference? Kim L Kelly, PharmD, BCPS, FCCP Define Variability VERY LOW GLYCEMIC VARIABILITY LOW GLYCEMIC VARIABILITY HIGH GLYCEMIC VARIABILITY So what s
More informationWhat s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016
What s the Goal? Individualizing Glycemic Targets Matthew Freeby M.D. December 3 rd, 2016 Diabetes Mellitus: Complications and Co-Morbid Conditions Retinopathy Between 2005-2008, 28.5% of patients with
More informationCategories of abnormal glucose homeostasis
Impaired Glucose Tolerance, but not Impaired Fasting Glucose, Is Associated With Increased Levels of Coronary Heart Disease Risk Factors Results From the Baltimore Longitudinal Study on Aging Deirdre R.
More informationHBA1C AS A MARKER FOR HIGH RISK DIABETIC SURGICAL PATIENT
Basrah Journal Of Surgery Bas J Surg, September, 18, 2012 HBA1C AS A MARKER FOR HIGH RISK DIABETIC SURGICAL PATIENT MB,ChB, DA, FICMS, Lecturer in Anesthesiology, Department of Surgery, College of Medicine,
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationand Training Standards for Diabetes Prevention [IMAGE] project) to provide
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Insulin Sensitivity, b-cell Function, and Incretin Effect in Individuals With Elevated 1-h Postload Plasma Glucose Levels MARIA A. MARINI,
More informationWhat s New. in Clinical Research
What s New in Clinical Research This new department features articles discussing recent developments in drug therapy, as well as review articles on specific drug therapies or disease states. Articles will
More informationLong-Term Care Updates
Long-Term Care Updates January 2019 By Kristina Nikl, PharmD Several recent studies evaluating the management of diabetes in older adults have concluded that 25-52% of elderly patients are currently being
More informationType 1 diabetes, although the most common
ADDRESSING THE 21ST CENTURY DIABETES EPIDEMIC * Based on a presentation by David M. Nathan, MD ABSTRACT Type 2 diabetes is an epidemic disorder. Although its complications can be treated, prevented, or
More information3. NEW DIAGNOSTIC CRITERIA, NEW CLASSIFICATION OF DM AND MODERN THERAPY APPROACH
3. NEW DIAGNOSTIC CRITERIA, NEW CLASSIFICATION OF DM AND MODERN THERAPY APPROACH 1.1 Introduction Ivana Pavlić-Renar, Ph.D. Vuk Vrhovac University Clinic, Zagreb, Croatia The current classification of
More informationGul-e-Raana and *Rukhshan Khurshid. Department of Biochemistry, Gujranwala Medical College and Fatima Jinnah Medical College, Lahore Pakistan
International Research Journal of Basic and Clinical Studies Vol. 1(2) pp. 16-21, February 2013 Available online http://www.interesjournals.org/irjbcs Copyright 2013 International Research Journals Full
More informationBariatric Surgery versus Intensive Medical Therapy for Diabetes 3-Year Outcomes
The new england journal of medicine original article Bariatric Surgery versus Intensive Medical for Diabetes 3-Year Outcomes Philip R. Schauer, M.D., Deepak L. Bhatt, M.D., M.P.H., John P. Kirwan, Ph.D.,
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationEfficacy & Safety of Repaglinide as Monotherapy or with Metformin in Achieving the Recommended Glycemic Targets of Type 2 Diabetes MMJ 2008; 7:4 8
Efficacy & Safety of Repaglinide as Monotherapy or with Metformin in Achieving the Recommended Glycemic Targets of Type 2 Diabetes MMJ 2008; 7:4 8 Tawfeeq F. R. AL Auqbi*, Esam N. S. Al Kirwi ** *F.I.C.M.S/C.M,**
More informationPostchallenge Glucose, HbA 1c, and Fasting Glucose as Predictors of Type 2 Diabetes and Cardiovascular Disease: A 10-year Prospective Cohort Study
Diabetes Care Publish Ahead of Print, published online June 23, 2010 A1C, Risk of Diabetes and CVD Postchallenge Glucose, HbA 1c, and Fasting Glucose as Predictors of Type 2 Diabetes and Cardiovascular
More informationDiabetes is one of the most costly and
Reviews/Commentaries/Position P O S I T I O N S T A T E M E N T Statements The Prevention or Delay of Type 2 Diabetes AMERICAN DIABETES ASSOCIATION AND NATIONAL INSTITUTE OF DIABETES, DIGESTIVE AND KIDNEY
More information